Counterfeit diabetes drugs have been in circulation since 2022, a problem affecting all regions of the world, the World Health Organisation, WHO, has warned. The health authority, in a statement, referred specifically to findings in Britain, the U.S. and Brazil since October 2023. The drug concerns Ozempic, a medicine containing the active ingredient semaglutide, which is also approved in the EU for the treatment of type 2 diabetes. The counterfeit version looks identical to the real medicine. Because the product also suppresses the appetite, it is increasingly being prescribed for weight loss…